Frontier Biotechnologies

6 articles about Frontier Biotechnologies

• Frontier Bio Leads Medical Innovation with "Lab-Grown" Blood Vessel Technology for Replacing Animal Testing

  10/24/2023

  Frontier Bio Corporation has unveiled a transformative method designed to fabricate living human blood vessels, setting the stage for a radical shift in medical device testing.

• FRONTIER BIOTECHNOLOGIES ANNOUNCES POSITIVE PHASE 1 RESULTS OF ITS FIRST CORONAVIRUS MAIN PROTEASE (MPRO) SMALL MOLECULE INHIBITOR, LAYING FOUNDATION FOR THE TREATMENT OF ACUTE AND LONG COVID

  8/8/2022

  Frontier Biotechnologies, announced positive results from the Phase 1 clinical trial of its drug candidate, FB2001 – a small molecule inhibitor of coronavirus main protease (Mpro) – in healthy adult volunteers.

• AFFiRiS and Frontier Biotechnologies announce license agreement for AFFITOPE®AT04, an active immunotherapy targeting PCSK9 to treat hypercholesterolemia, in Greater China

  1/3/2022

  Frontier Biotechnologies obtains exclusive rights to develop and commercialize AFFITOPE® AT04 in Greater China.

• Frontier Biotechnologies Licenses 3BNC117, A Novel Broad-Spectrum HIV Neutralizing Antibody

  7/25/2017

• Frontier Biotechnologies Of Nanjing Announces $43 Million Funding

  1/6/2017

• Frontier Biotechnologies Reports Primary Endpoint Met In Phase 2 Trial Of AB001 In Chronic Low Back Pain

  6/22/2016